New hope for bipolar depression? pramipexole trial targets anhedonia

NCT ID NCT07664852

Not yet recruiting Symptom relief Sponsor: Daniel Lindqvist Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This Phase 3 trial tests whether pramipexole, a dopamine-boosting drug, can ease anhedonia (loss of pleasure) in people with bipolar depression. 126 participants will receive either pramipexole or a placebo alongside their usual mood stabilizer for 6 weeks. The study aims to improve mood and potentially reduce suicide risk.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pramipexole
What this could lead to: If successful, this could provide a new treatment option for bipolar depression, potentially reducing suffering and lowering suicide risk.
What could go wrong: This is an early-stage Phase 3 trial with only 126 participants. Results may not confirm earlier promising findings, and pramipexole can cause side effects like nausea or dizziness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIPOLAR DEPRESSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Anhedonia bipolar depression bipolar disorder bipolar I disorder bipolar II disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BIPOLAR DISORDER (BD)

Contacts and locations

Locations

Adult Psychiatry

Lund, Skåne County, 22240, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.